Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse in Patients with Hematologic Malignancies

Table 1

Patients with 100% donor chimerism in lymphocytes and PMN with mixed (donor and recipient) plasma chimerism.

Patient	PMN	Lymph	Plasma donor ratio	Diagnosis	Status
1	100	100	30	AML	Death in remission
2	100	100	38.8	CML	BCR-ABL: 0.56
3	100	100	52.5	CML	BCR-ABL: 3.7
4	100	100	57	AML	EM disease
5	100	100	60	CML	BCR-ABL: 0.003
6	100	100	64.5	ALL	Relapse
7	100	100	66.9	AML	Relapse
8	100	100	68.4	ALL	FISH 3% monosomy 17
9	100	100	69.4	ALL	Relapse
10	100	100	74.4	CML	CR
11	100	100	75	CML	BCR-ABL: 0.03
12	100	100	76	AML	CR
13	100	100	76.2	ALL	10% by FISH t(1; 19)
14	100	100	76.5	ALL	CR
15	100	100	78.3	CML	BCR-ABL: 3.57 one month earlier
16	100	100	79.9	ALL	CR
17	100	100	80	AML	CR
18	100	100	80	AML	CR
19	100	100	80	ALL	CR
20	100	100	81.7	ALL	CR
21	100	100	82	AML	CR
22	100	100	82.4	AML	CR
23	100	100	84.3	AML	Relapse
24	100	100	84.6	AML	CR
25	100	100	84.7	AML	CR
26	100	100	88.1	ALL	CR
27	100	100	88.4	ALL	EM disease
28	100	100	89.3	AML	CR
29	100	100	89.4	AML	CR
30	100	100	90	CML	CR
31	100	100	90	AML	Relapse
32	100	100	90	ALL	CR
33	100	100	90	ALL	CR
34	100	100	90	AML	CR

PMN: polymorphonuclear cells; EM: extramedullary.